Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Spero Therapeutics Community
NasdaqGS:SPRO Community
1
Narratives
written by author
0
Comments
on narratives written by author
24
Fair Values set
on narratives written by author
Community Investing Ideas
Spero Therapeutics
Popular
Undervalued
Overvalued
Spero Therapeutics
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
Positive Phase III Efficacy Will Unlock Expanded Antibiotic Markets
Key Takeaways Successful late-stage results and strategic partnerships could propel revenue growth, reduce fixed costs, and stabilize near-term cash flow. Favorable regulatory landscape and market demand for novel antibiotics position the company for sustained expansion and margin improvement.
View narrative
US$5.00
FV
63.2% undervalued
intrinsic discount
-10.15%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
20
users have followed this narrative
6 days ago
author updated this narrative
Your Valuation for
SPRO
SPRO
Spero Therapeutics
Your Fair Value
US$
Current Price
US$1.84
63.5% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-113m
118m
2015
2018
2021
2024
2025
2027
2030
Revenue US$79.8m
Earnings US$16.6m
Advanced
Set Fair Value